Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

667 trials with published results (27%)

Research Maturity

1614 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

8.3%

207 terminated out of 2496 trials

Success Rate

88.6%

+2.1% vs benchmark

Late-Stage Pipeline

24%

587 trials in Phase 3/4

Results Transparency

41%

667 of 1614 completed with results

Key Signals

667 with results89% success207 terminated

Data Visualizations

Phase Distribution

1,719Total
Not Applicable (462)
Early P 1 (11)
P 1 (283)
P 2 (376)
P 3 (330)
P 4 (257)

Trial Status

Completed1,614
Unknown345
Terminated207
Recruiting139
Active Not Recruiting76
Withdrawn50

Trial Success Rate

88.6%

Benchmark: 86.5%

Based on 1614 completed trials

Clinical Trials (2496)

Showing 20 of 20 trials
NCT03649178Not ApplicableCompletedPrimary

Dietary Salt in Rheumatoid Arthritis

NCT07201558Phase 1RecruitingPrimary

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07207954Phase 1RecruitingPrimary

Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis

NCT07295847Phase 1Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT03025308Phase 3CompletedPrimary

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

NCT07137598Phase 2RecruitingPrimary

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07534332Phase 2Not Yet RecruitingPrimary

Disulfiram in Rheumatoid Arthritis

NCT07620392Phase 2RecruitingPrimary

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

NCT06916806Phase 1Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT07712939Phase 1Recruiting

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

NCT05936970Active Not RecruitingPrimary

Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

NCT07180537Not ApplicableRecruitingPrimary

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07363590Phase 1Recruiting

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

NCT07171983Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

NCT07715045Phase 2CompletedPrimary

Umbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled Trial

NCT05306353Phase 2TerminatedPrimary

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT02281747Active Not RecruitingPrimary

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT04692493Phase 3RecruitingPrimary

RA-PRO PRAGMATIC TRIAL

NCT00055055CompletedPrimary

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

NCT07276958Phase 1Recruiting

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Scroll to load more

Research Network

Activity Timeline